Amneal Pharmaceuticals (AMRX) Assets Average (2018 - 2026)

Amneal Pharmaceuticals' Assets Average history runs 9 years deep, the most recent figure standing at $3.6 billion for Q1 2026.

• On a quarterly basis, Assets Average rose 5.12% year-over-year to $3.6 billion in Q1 2026; TTM through Mar 2026 was $3.6 billion, a 5.12% increase from a year earlier, with the FY2025 full-year figure at $3.6 billion, up 2.95% from the prior year.
• Assets Average declined to $3.6 billion in Q1 2026 per AMRX's latest filing, from $3.6 billion in the prior quarter.
• Across five years, Assets Average topped out at $4.0 billion in Q2 2022 and bottomed at $3.4 billion in Q2 2025.
• The 5-year median for Assets Average is $3.6 billion (2026), against an average of $3.6 billion.
• Across the five-year window, Assets Average retreated 7.6% in 2023 and grew 5.12% in 2026, its largest moves.
• Year by year, Assets Average stood at $3.8 billion in 2022, then slipped by 6.69% to $3.6 billion in 2023, then fell by 2.75% to $3.5 billion in 2024, then rose by 4.53% to $3.6 billion in 2025, then dropped by 0.82% to $3.6 billion in 2026.
• Per Business Quant, the three latest AMRX Assets Average figures stand at $3.6 billion (Q1 2026), $3.6 billion (Q4 2025), and $3.5 billion (Q3 2025).